Contracted analytical and efficacy evaluation testing for external companies
First written in FY2019-Q3. 6 of 10 entries say "Advanced", first in FY2023-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In addition to the existing service covering immunology and oncology, analysis targeting the neurological field has started as a new product under the Olink service, which can analyze minute changes in proteins.」
In the research support business, the scope of Olink services was expanded from the immune and cancer fields to the neuroscience field, and a new analytical service was launched. - 2026-09-11AdvancedRevision of earnings forecasts
「In addition to the existing service covering immunology and oncology, analysis targeting the neurological field has started as a new product under the Olink service, which can analyze minute changes in proteins.」
The Olink service has expanded into the neurological field, with a new service launched. - FY2024-Q1AdvancedAnnual report
「During the first quarter of the fiscal year, the Company introduced the latest model from Thermo Fisher Scientific and launched a service offering higher precision and shorter turnaround times than before. Orders for the Olink Target and Olink Flex services, which can analyze changes in trace amounts of proteins, also remained firm among domestic research institutions, pharmaceutical companies and other customers, contributing to revenue generation in the biomedical business.」
The Company introduced the latest model from Thermo Fisher Scientific and launched a high-precision, short-turnaround proteomic analysis service. Orders for Olink Target and Olink Flex also remained firm, contributing to revenue generation. - FY2023AdvancedAnnual report
「In February 2023, the Company launched the new Olink Flex service. Olink Flex is a customizable solution that can be tailored to customer needs and enables more targeted protein analysis. In July 2023, the Company also began a business partnership with TAKARA BIO INC., which provides the Olink Explore service. Through joint promotional activities, the Company established a structure capable of meeting customer needs through a one-stop solution.」
The launch of the new Olink Flex service and the business partnership and joint promotion for Olink Explore with TAKARA BIO INC. expanded the scope of the research support services and the sales structure. - FY2023-Q2AdvancedAnnual report
「Orders for the Olink Target service have been growing steadily from domestic research institutions, pharmaceutical companies and other customers, contributing to higher revenue in the biomedical business.」
Orders for the Olink Target contract service launched in Japan have grown from research institutions, pharmaceutical companies and other customers, contributing to revenue growth. - FY2023-Q1AdvancedAnnual report
「In June 2022, the Company became the first in Japan to launch the OlinkⓇ Target contract service, which can analyze changes in trace amounts of proteins, to further strengthen its proteomic analysis capabilities.」
The Company became the first in Japan to launch a contract service using Olink Target for analytical and evaluation services for external companies. - FY2021-Q3RestatedAnnual report
「In the biomedical business, in addition to producing antibodies against new drug-discovery targets, the Company operates an LSI (Life Science Information) business that conducts analytical and efficacy evaluation testing under contract for external companies. However, contract testing decreased because the Company refrained from accepting orders for such testing in order to focus on the research and development of new drug-discovery targets.」
The Company reconfirms that it is prioritizing research and development of new drug-discovery targets and refraining from contract testing for external companies. - FY2021-Q2RestatedAnnual report
「In the biomedical business, in addition to producing antibodies against new drug-discovery targets, the Company operates an LSI (Life Science Information) business that conducts analytical and efficacy evaluation testing under contract for external companies. However, contract testing decreased because the Company refrained from accepting orders for such testing in order to focus on the research and development of new drug-discovery targets.」
The Company reconfirms that it is prioritizing research and development of new drug-discovery targets and refraining from accepting orders for contract testing. - FY2021-Q1SoftenedAnnual report
「In the biomedical business, in addition to producing antibodies against new drug-discovery targets, the Company operates an LSI (Life Science Information) business that conducts analytical and efficacy evaluation testing under contract for external companies. However, contract testing decreased because the Company refrained from accepting orders for such testing in order to focus on the research and development of new drug-discovery targets.」
Contract testing declined because the Company prioritized research and development of new drug-discovery targets and refrained from accepting orders for contract testing from external companies. - FY2019-Q3First statedAnnual report
「In addition, in the biomedical business, the Company produces antibodies against new drug-discovery targets and conducts analytical and efficacy evaluation testing under contract for external companies.」
The Company explicitly identifies contract analytical and efficacy evaluation testing for external companies as a business activity in addition to drug-discovery research.